Evolus Inc. today announced that the European commercial launch of its Estyme injectable hyaluronic acid gel collection is set for May 16.
The launch will mark the Newport Beach aesthetics’ company entry into the international dermal filler market, it said.
“With the commercial launch of Estyme, we are entering a new phase of growth as a multi-product aesthetics company in Europe,” David Moatazedi, chief executive and president of Evolus, said in a statement.
In 2023, Evolus announced it was partnering with French company Symatese Aesthetics to create a line of five dermal fillers. The collection includes Estyme Smooth and Estyme Form, which are currently marketed in the U.S. under Evolysse, as well as Estyme Lips and Estyme Sculpt.
Shares in Evolus rose nearly 1% to $6.40 apiece and a $421 million market cap (Nasdaq: EOLS).
